Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Ghiringhelli

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
Journal of Geriatric Oncology|January 18, 2020
Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and FranceArielle Elkrief, Corentin Richard, Julie Malo, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal CancerMichael Cecchini, Sae-Won Han, Soohyeon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2026
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancerByoung Chul Cho, Sun Min Lim, Sang Hoon Lee, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.
Immunity|March 13, 2012
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expressionFanny Chalmin, Grégoire Mignot, Mélanie Bruchard, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
The EMBO Journal|April 20, 2019
Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2Julien Cherfils-Vicini, Charlene Iltis, Ludovic Cervera, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
Journal of Geriatric Oncology|January 18, 2020
Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and FranceArielle Elkrief, Corentin Richard, Julie Malo, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal CancerMichael Cecchini, Sae-Won Han, Soohyeon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2026
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancerByoung Chul Cho, Sun Min Lim, Sang Hoon Lee, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.
Immunity|March 13, 2012
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expressionFanny Chalmin, Grégoire Mignot, Mélanie Bruchard, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
The EMBO Journal|April 20, 2019
Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2Julien Cherfils-Vicini, Charlene Iltis, Ludovic Cervera, et al.
Pageof 10